Potential HCV Blockbuster, Strong Fundraising Place Vertex In Enviable Position
This article was originally published in The Pink Sheet Daily
Executive Summary
Well-financed biotech looks set to advance telaprevir and CF candidate despite tough financial markets.
You may also be interested in...
Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say
The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product
Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say
The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product
Telaprevir Simmering, Flush Vertex Raises $320 Million More
Firm moves away from “science-based” buyers and herds three institutional, longer-view backers into a single public offering.